Retinal Pharmacotherapy book cover

Retinal Pharmacotherapy

Retinal Pharmacotherapy is the first comprehensive book devoted to pharmacologic agents and their rationale and mechanisms of action in selected retinal and uveitic diseases. Drs. Quan Dong Nguyen, Eduardo Buchele Rodrigues, Michel Eid Farah, and William F. Mieler lead an international team of expert contributors to present up-to-date knowledge of new drugs on the market, the science behind the drugs, evidence of how the drugs work, and the reasons why they are effective or not. This user-friendly, all-in-one reference provides you with easy access to practical information on the effective and appropriate use of pharmacologic agents in the management of retinal diseases.

Audience

Opthalmology, Optometrist

Hardbound, 408 Pages

Published: February 2010

Imprint: Saunders

ISBN: 978-1-4377-0603-1

Contents

  • 1 Evolving Knowledge in Pharmacologic
    Treatments

    Section 1: Basic Sciences in Retina

    2 Retinal Anatomy and Pathology

    3 Retinal Biochemistry, Physiology and
    Cell Biology

    4 Ocular Angiogenesis: Vascular Endothelial
    Growth Factor and Other Factors

    5 Ocular Immunity and Inflammation

    6 Complement Activation and Inhibition in
    Retinal Disease

    7 Genetics of Retinal Disease

    Section 2: Animal Models and Routes for
    Retinal Drug Delivery

    8 Vitamins and Supplements for Age-Related
    Macular Degeneration

    9 Ocular Pharmacokinetic, Drug Bioavailability and Intraocular Drug Delivery Systems

    0 Routes for Drug Delivery to the Eye and Retina: Intravitreal Injections and Vitrectomy

    11 Routes for Drug Delivery: Topical, Transscleral, Suprachoroidal, and Intravitreal
    Gas-Phase Nanoparticles

    12 Routes for Drug Delivery: Sustained-Release
    Devices

    13 Microspheres and Nanotechnology for
    Drug Delivery

    14 Thermo-sensitive Hydrogels

    15 Retina and Ocular Toxicity to Ocular Application
    of Drugs

    16 Retinal Toxicity of Systemic and Topical
    Medications

    Section 3: Retinal Diseases Amenable to Pharmacotherapy

    17 Non-neovascular Age-Related Macular
    Degeneration

    18 Neovascular Age-Related Macular Degeneration

    19 Diabetic Retinopathy and Diabetic
    Macular Edema

    20 Retinal Vein Occlusion

    21 Retinal Detachment and Proliferative
    Vitreoretinopathy

    22 Posterior Uveitis

    23 Choroidal Neovascularization Secondary
    to Inflammation, Infection, and Myopia

    24 Ocular Infection: Endophthalmitis

    25 Retinopathy of Prematurity

    26 Idiopathic Macular Telangiectasia

    27 Neovascular Glaucoma

    28 Retinal Hereditary and Degenerative /
    Dystrophic Diseases (non-AMD)

    Section 4: Drugs and Mechanisms in
    Retinal Diseases

    29 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    in the Treatment of Retinal Diseases

    30 Corticosteroids: Triamcinolone, Dexamethasone, Fluocinolone, and Others

    31 Anecortave Acetate

    32 Therapeutic Monoclonal Antibodies and
    Fragments: Bevacizumab

    33 Therapeutic Monoclonal Antibodies and
    Fragments: Ranibizumab

    34 Pathophysiology of Vascular Endothelial Growth
    Factor and Other Angiogenic Molecules

    35 Biologic Therapies: Infliximab, Adalimumab,
    Etanercept, Daclizumab, and Others

    36 Immunomodulatory Therapy in Uveitis

    37 Fusion Proteins: VEGF-Trap

    38 Aptamers and Intramers: Pegaptanib

    39 Protein Kinase C Inhibitor: Ruboxistaurin

    40 Small-Interference RNA Technology: SIRNA 027, Bevasiranib, and REDD14NP

    41 Ocular Gene Therapy

    42 Neuroprotection and Retinal Diseases

    43 Photosensitizers and Photodynamic Therapy:
    Verteporfin

    44 Chemotherapy for Malignant Intraocular Tumors

    45 Antibiotics

    Section 5: Pharmacotherapy and Surgery

    46 Rheotherapy (Rheopheresis; Therapeutical
    Apheresis)

    47 Enzymatic Vitrectomy and Pharmacologic
    Vitreodynamics

    48 The Use of Vital Dyes during Vitreoretinal Surgery - Chromovitrectomy

    49 Epimacular and External Radiotherapy

    50 Current Status of Human Retinal Pigment
    Epithelial Transplantation

    Section 6: The Last Words

    51 Off-Label Drugs and the Impact of the Food and
    Drug Administration in the Treatment of
    Retinal Disease

    52 Value-Based Medicine and Pharmacoeconomics

    53 Future Perspectives: Agents on the Horizon

Advertisement

advert image